SCHEMBL5463167

SCHEMBL5463167

Cc1nc(N[C@H]2CCC[C@H](N)C2)nc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 3/20 0.49
NPY5R Q15761 1/20 0.48
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CDK2 P24941 2/20 0.45
CDC7 O00311 1/20 0.45
DAPK3 O43293 1/20 0.45
JAK2 O60674 1/20 0.45
ROCK2 O75116 1/20 0.45
PRKD3 O94806 1/20 0.45
MAP4K4 O95819 1/20 0.45
PAK4 O96013 1/20 0.45
PIM1 P11309 1/20 0.45
PRKACA P17612 1/20 0.45
FLT3 P36888 1/20 0.45
CSNK1A1 P48729 1/20 0.45
CDK8 P49336 1/20 0.45
CLK2 P49760 1/20 0.45
GSK3A P49840 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5463157 1.00 PTPN11 (0.49) PTPN11NPY5RLMNASMN1; SMN2KDM4E
SCHEMBL5463162 1.00 PTPN11 (0.49) PTPN11NPY5RLMNASMN1; SMN2KDM4E
SCHEMBL5459846 0.85 MCHR1 (0.52) NPY5RCDK2CDC7DAPK3JAK2
SCHEMBL13793907 0.83 APP (0.52) PTPN11NPY5RLMNASMN1; SMN2KDM4E
SCHEMBL13793576 0.83 APP (0.52) PTPN11NPY5RLMNASMN1; SMN2KDM4E
SCHEMBL5943477 0.81 KDM4E (0.74) LMNASMN1; SMN2KDM4EHTTALDH1A1
SCHEMBL5528796 0.77 MCHR1 (0.56) NPY5RAPPBCHEACHE
SCHEMBL5528801 0.77 MCHR1 (0.56) NPY5RAPPBCHEACHE
SCHEMBL13793565 0.75 CYP1A2 (0.56) NPY5RLMNASMN1; SMN2KDM4EPAK4
SCHEMBL13793109 0.75 APP (0.52) PTPN11NPY5RHSD17B10TSHRAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185119-A1 Therapeutic agents II ASTRAZENECA AB (SE) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185119-A1 Therapeutic agents II HTT, ACHE, GPR119 PTPN11 4596/4885NPY5R 2575/4885LMNA 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.